Table 2.

Univariate Cox Regression Analysis of Prognostic Factors for Overall Survival in ED-SCLC

	N	AAPR < 0.35	AAPR ≥ 0.35	Total
Age Group
<60	100	1.0	1.0	1.0
≥60	124	1.54 (0.79, 2.99) 0.2044	1.08 (0.74, 1.59) 0.6859	1.21 (0.87, 1.69) 0.255
Sex
Male	197	1.0	1.0	1.0
Female	27	3.92 (0.89, 17.21) 0.0699	0.65 (0.37, 1.15) 0.1366	0.75 (0.44, 1.27) 0.285
Smoking History
Never	40	1.0	1.0	1.0
Ever	179	0.83 (0.36, 1.92) 0.6667	1.40 (0.86, 2.30) 0.1783	1.23 (0.80, 1.88) 0.340
Unknow	5	3.29 (0.64, 16.97) 0.1551	1.58 (0.47, 5.34) 0.4600	1.97 (0.76, 5.15) 0.164
ECOG
0–1	170	1.0	1.0	1.0
≥2	31	1.21 (0.37, 4.00) 0.7529	1.25 (0.71, 2.21) 0.4457	1.27 (0.76, 2.12) 0.366
Bone Metastasis
No	159	1.0	1.0	1.0
Yes	65	1.25 (0.65, 2.41) 0.5064	1.41 (0.84, 2.36) 0.1890	1.32 (0.88, 1.98) 0.184
Brain Metastasis
No	187	1.0	1.0	1.0
Yes	37	1.54 (0.54, 4.44) 0.4193	0.94 (0.49, 1.82) 0.8581	1.05 (0.60, 1.83) 0.876
Lung Metastasis
No	161	1.0	1.0	1.0
Yes	63	1.14 (0.50, 2.63) 0.7503	1.16 (0.69, 1.94) 0.5703	1.15 (0.75, 1.79) 0.523
Liver Metastasis
No	169	1.0	1.0	1.0
Yes	55	2.69 (1.28, 5.67) 0.0091	2.11 (1.20, 3.70) 0.0092	2.35 (1.51, 3.64) 0.0001
Adrenal Gland Metastasis
No	187	1.0	1.0	1.0
Yes	37	4.47 (1.27, 15.80) 0.0200	1.88 (0.97, 3.66) 0.0616	2.15 (1.20, 3.86) 0.01
Malignant Pleural Effusion
No	154	1.0	1.0	1.0
Yes	70	1.54 (0.78, 3.05) 0.2134	1.50 (0.93, 2.44) 0.0998	1.50 (1.01, 2.23) 0.042
Efficacy of First-Line Treatment
PR	106	1.0	1.0	1.0
SD	37	1.68 (0.70, 4.06) 0.2480	1.55 (0.91, 2.64) 0.1073	1.60 (1.01, 2.52) 0.043
PD	13	18.19 (4.99, 66.33) <0.0001	1.27 (0.46, 3.55) 0.6462	2.51 (1.19, 5.30) 0.016
Sum of Metastasis Organs
<2	137	1.0	1.0	1.0
≥2	87	1.98 (1.04, 3.77) 0.0382	1.23 (0.82, 1.83) 0.3180	1.41 (1.01, 1.98) 0.043

Abbreviations: AAPR, albumin-to-alkaline phosphatase ratio; ED-SCLC, extensive-disease small-cell lung cancer; ECOG PS, Performance Status of East Cooperative Oncology Group; PR, partial response; SD, stable disease; PD, disease progression.